Background Introducing new methodology often requires alteration to reference ranges and may cause inconvenience. Reagent suppliers may not have validated reference ranges quoted in their method sheets. When ratios of analytes are important, as for conjugated and unconjugated bilirubin, the combined changes can cause confusion.
Introduction
Conjugated bilirubin (or direct-reacting bilirubin) measurements are known to be method-dependent. 1 Yet in practice, the reality of changing instrumentation can lead to confusion if all parties concerned are not forewarned and prepared for the consequences of the changing assay characteristics.
Methods
The authors' laboratory recently changed from Ortho-Clinical Diagnostics (High Wycombe, UK) Vitros dry slide technology (Bc slide) to the Bayer (Newbury, UK) ADVIA 1650 method. The Vitros method for conjugated bilirubin exploits the unique spectral characteristics of conjugated and unconjugated bilirubin when bound to a mordant layer on the slide. Re£ection densities at 400 nm and 460 nm were used to determine the relative concentrations of conjugated and unconjugated bilirubin. Delta bilirubin was not measured. A total bilirubin slide based on the diazo method was also available. The Bayer method for direct bilirubin using the diazo reaction (endpoint) is based on the procedure of Jendrassik and Grof. Both manufacturers quoted essentially identical reference ranges and fundamental di¡erences in performance for di¡erent patient groups were not anticipated. It was incorrectly assumed that the reference ranges quoted with the method sheets had been validated by both manufacturers.We were advised that the source for the Bayer ADVIA method was the third edition of Tietz. 2 Reference ranges and the total coe⁄cients of variation (CVs) for direct/conjugated bilirubin assays, which were concentration-dependent, are listed below: Samples that were sent for comparison to the University Hospital Lewisham for conjugated and total bilirubin measurement by the Vitros method were protected from light and analysed within 24 h. Two samples were also returned and re-analysed by the Bayer method. No sample deterioration had occurred.
Results
Following the change of instrumentation, problems arose with the interpretation of some neonatal bilirubin results. A larger proportion of serum samples from neonates with hyperbilirubinaemia had signi¢cant amounts of direct-reacting bilirubin with the Bayer instrumentation, which caused interpretative complications depending on age and degree of hyperbilirubinaemia. Analysis at a neighbouring laboratory (Lewisham), which used the Vitros (Bc) method, con-¢rmed that this problem was method related.
As time passed, a second problem patient group emerged. These were either young people under 25 years on no medication, or adults over 45 years requiring regular medication and monitoring of liver function tests (LFTs). These patients presented with slight hyperbilirubinaemia (26--54 mmol/L) but otherwise normal LFTs. When direct-reacting bilirubin was measured, all results were well above the reference range and constituted 21--35% of the total bilirubin (Table 1) . Had such results been obtained with theVitros dry slide technology, this would have excluded Gilbert's syndrome --commonly occurring and an otherwise likely explanation. The General Practitioners (GPs) from whom all the requests except one had arisen began to request further investigations, which included serological testing for viral infections: CMV, EBV, HBV, HAV, leptospirosis, parvovirus and immunoglobulin subclasses. All results were normal or negative.
The GPs became concerned regarding the possibility of liver disease of unknown aetiology and whether it was appropriate to continue to prescribe medication such as statins for these patients. Finally, the GPs requested genetic testing for Gilbert's syndrome. This was carried out at the Liverpool Women's Hospital. Two school-aged patients presenting with hyperbilirubinaemia had been 'run down' for some time and the 48-h fasting protocol for Gilbert's syndrome 3 was not received with enthusiasm. All but two of the older patients were on statins and had already had fasting lipid and LFT pro¢les. The need to fast may have exaggerated their hyperbilirubinaemia. Results of the genetic testing were consistent with Gilbert's syndrome (in which conjugated bilirubin is detectable only by highperformance liquid chromatography [HPLC] and delta bilirubin is absent) for all of these patients.
Discussion
Most methods over-estimate conjugated bilirubin compared to HPLC, 4 except for the Vitros dry slide technique. This is presumed to be because delta bilirubin contributes to the direct diazo reaction, but cannot be the explanation in Gilbert's syndrome. Data from the external paediatric bilirubin quality assurance scheme suggest that the dry slide technology under-recovers conjugated bilirubin. However, bilirubin ditaurate is used as the spike. Recent work 5 (performed in China where bilirubin ditaurate is apparently not used as a calibrator) has shown that puri¢ed conjugated bilirubin behaves di¡erently from this substitute in the direct reaction using the Doumas modi¢cation of Jendrassik and Grof, despite near-identical absorption spectral characteristics of their azopigments. These researchers demonstrated that the matrix used for diluting conjugated bilirubin a¡ected its participation in the direct reaction. They concluded that conjugated bilirubin, rather than ditaurobilirubin, more closely resembles the direct reaction in patient's samples. Our own examination of reaction absorbance changes (Bayer method) had shown that the direct reaction proceeded to its endpoint more rapidly for calibrators and quality control materials than for patient's samples. It was noted that the Bayer method gave higher total bilirubin values than the Vitros method. This had been observed in our work-up, but the positive bias is less marked for National External Quality Control (NEQAS) samples. For patient's samples with total bilirubin values in the range 5--55 mmol/L, the regression equation was:
Bayer bilirubin ¼ 1:32 Vitros bilirubin À 0:45 mmol=L For EQA material the relationship ðin our handsÞ was: Bayer bilirubin¼1:10 Vitros bilirubin method mean þ3:2 mmol=L:
When samples from patients with liver disease were analysed for direct or conjugated bilirubin, a linear regression was obtained at high values using both methods, but the Vitros method did not detect any conjugated bilirubin unless the Bayer method reading was above 15 mmol/L. It therefore appears likely that we have changed from a method which correlated well with HPLC 6 to one with signi¢cant over-estimation for serum samples.
Other workers have illustrated how varying proportions of the various molecular species of bilirubin can a¡ect reaction kinetics. 7 It is possible that the explanation for some of our observations lies with the proportions of the various molecular species or with the read times selected for the direct diazo reaction or matrix effects. Whatever the explanation, it is desirable for the manufacturer to provide more detailed information regarding assay performance in speci¢c patient groups. This report gives the range of values observed for direct-reacting bilirubin in Gilbert's syndrome using Bayer ADVIA methodology if the method is run as currently recommended by the manufacturer.
Conclusions
It is important to establish whether manufacturers have validated the reference ranges they supply.
The combination of signi¢cant positive bias and reference range uncertainty for direct bilirubin with the Bayer analyser caused delays in identifying patients with Gilbert's syndrome.
As manufacturers may not have access to patients' samples, exchanging and publishing data by method for di¡erent patient groups will become increasingly important.
